Cargando…

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies

Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse r...

Descripción completa

Detalles Bibliográficos
Autores principales: Freedman, Mark S, Wolinsky, Jerry S, Comi, Giancarlo, Kappos, Ludwig, Olsson, Tomas P, Miller, Aaron E, Thangavelu, Karthinathan, Benamor, Myriam, Truffinet, Philippe, O’Connor, Paul W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891690/
https://www.ncbi.nlm.nih.gov/pubmed/28304217
http://dx.doi.org/10.1177/1352458517695468
_version_ 1783313043441057792
author Freedman, Mark S
Wolinsky, Jerry S
Comi, Giancarlo
Kappos, Ludwig
Olsson, Tomas P
Miller, Aaron E
Thangavelu, Karthinathan
Benamor, Myriam
Truffinet, Philippe
O’Connor, Paul W
author_facet Freedman, Mark S
Wolinsky, Jerry S
Comi, Giancarlo
Kappos, Ludwig
Olsson, Tomas P
Miller, Aaron E
Thangavelu, Karthinathan
Benamor, Myriam
Truffinet, Philippe
O’Connor, Paul W
author_sort Freedman, Mark S
collection PubMed
description Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse rate and disability worsening across patient subgroups defined according to prior disease-modifying therapy exposure. This analysis provides further supportive evidence for a consistent effect of teriflunomide across a broad range of patients with relapsing MS, including patients who have used and discontinued other disease-modifying therapies.
format Online
Article
Text
id pubmed-5891690
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-58916902018-04-13 The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies Freedman, Mark S Wolinsky, Jerry S Comi, Giancarlo Kappos, Ludwig Olsson, Tomas P Miller, Aaron E Thangavelu, Karthinathan Benamor, Myriam Truffinet, Philippe O’Connor, Paul W Mult Scler Short Reports Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse rate and disability worsening across patient subgroups defined according to prior disease-modifying therapy exposure. This analysis provides further supportive evidence for a consistent effect of teriflunomide across a broad range of patients with relapsing MS, including patients who have used and discontinued other disease-modifying therapies. SAGE Publications 2017-03-17 2018-04 /pmc/articles/PMC5891690/ /pubmed/28304217 http://dx.doi.org/10.1177/1352458517695468 Text en © The Author(s), 2017 http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Short Reports
Freedman, Mark S
Wolinsky, Jerry S
Comi, Giancarlo
Kappos, Ludwig
Olsson, Tomas P
Miller, Aaron E
Thangavelu, Karthinathan
Benamor, Myriam
Truffinet, Philippe
O’Connor, Paul W
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
title The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
title_full The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
title_fullStr The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
title_full_unstemmed The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
title_short The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
title_sort efficacy of teriflunomide in patients who received prior disease-modifying treatments: subgroup analyses of the teriflunomide phase 3 temso and tower studies
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891690/
https://www.ncbi.nlm.nih.gov/pubmed/28304217
http://dx.doi.org/10.1177/1352458517695468
work_keys_str_mv AT freedmanmarks theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT wolinskyjerrys theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT comigiancarlo theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT kapposludwig theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT olssontomasp theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT milleraarone theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT thangavelukarthinathan theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT benamormyriam theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT truffinetphilippe theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT oconnorpaulw theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT freedmanmarks efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT wolinskyjerrys efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT comigiancarlo efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT kapposludwig efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT olssontomasp efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT milleraarone efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT thangavelukarthinathan efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT benamormyriam efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT truffinetphilippe efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT oconnorpaulw efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies
AT efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies